



For immediate distribution
Source: DIAGNOS inc.

2012.09.20

DIAGNOS signs first clinical client contract in VietNam for diabetic retinopathy screening using CARA

Brossard, Quebec, Canada – September 20, 2012 - DIAGNOS inc. (“DIAGNOS” or “the Corporation”) (TSX Venture: ADK), leader in algorithm development, data analysis, and image processing announces that it has signed a services contract with Vung Tau Ophthalmological Clinic, Vung Tau, VietNam, for diabetic retinopathy screening using CARA. CARA’s local representative in VietNam, Alphi Investment (“ALPHI”) was instrumental in concluding the agreement.

The CARA suite of applications allows the different players in the diabetic retinopathy screening process to make better informed decisions and extend cost-effective care to a larger patient population. “Our global market penetration strategy is to address countries with a high prevalence of diabetes, VietNam being one of those markets. The Managing Director of ALPHI, Mr. Nguyen Quang Quy, has helped many Canadian companies develop new business opportunities in Vietnam.” said Andre Larente, President of DIAGNOS.

According to a 2010 study conducted in Vietnam by Dr. Ta Van Binh, PhD, MD, Director of the Vietnam Ministry of Health, National Institute of Diabetes and Metabolic Disorders, the prevalence of diabetes has increased by 500% over the last decade and the number of individuals affected by this disease is now estimated at 3.5 to 4.0 million.

The Corporation has decided to provide its application in the local language, Vietnamese, effectively expanding the addressable user base and prospective penetration in VietNam. Most doctors in VietNam do not speak English and this was making our solution only attractive to a minority population. Management is confident that CARA will generate new streams of revenue in VietNam based on the following factors: large diabetic patient population in need of retinopathy screening, relative absence of local resources to meet this need, our presence in the local market with an established local representative since 2011, and a version of our platform adapted to local language and conditions. The present agreement represents the first of a list of qualified prospects who are in the approval and budgeting process.

About CARA

CARA is a tele-ophthalmology platform that integrates with existing equipment (hardware and software) and processes at the point of care (POC) and comprises: image upload, image enhancement automated pre-screening, grading by a specialist, and referral to a specialist. CARA’s image enhancement algorithms make standard retinal images sharper, clearer, and easier to read. CARA is accessible securely over the internet, and is compatible with all recognized image formats and brands of fundus cameras, and is EMR compatible. CARA is a cost-effective tool for screening large numbers of patients, in real-time and has been approved by regulatory authorities including Health Canada, US Food and Drug Administration, and the European Union.

About ALPHI

Alphi Investment is a Vietnamese Investment company. ALPHI’s mission is to help Canadian and Vietnamese organizations put in place bilateral cooperation agreements in the fields of healthcare and technology.



For immediate distribution
Source: DIAGNOS inc.

About DIAGNOS

Founded in 1998, DIAGNOS is a publicly traded Canadian corporation with a mission to commercialize technologies combining contextual imaging and traditional data mining thereby improving decision making processes. DIAGNOS offers products, services, and solutions to clients in a variety of fields including natural resources, healthcare, and entertainment.

The TSX Venture Exchange has not reviewed and does not accept responsibility for the adequacy or accuracy of this press release.

For further information, please visit our website at www.diagnos.com or the SEDAR website at www.sedar.com. You may also contact our investor relations representative:

André Larente, President – DIAGNOS inc.
Tel: 1-877-678-8882 or (450) 678-8882, ext.: 224
alarente@diagnos.com

Louis Morin, Bid Capital Markets
Tel : 514-845-1101
bidcapital@videotron.ca